| Reference | </br>1:Meta-analysis comparing the efficacy of nedaplatin-based regimens between squamous cell and non-squamous cell lung cancers. Tian Y, Liu Q, Wu K, Chu Q, Chen Y, Wu K.Oncotarget. 2017 Apr 28. doi: 10.18632/oncotarget.17499. [Epub ahead of print] PMID: 28504964 Free Article</br>2:A Low Psoas Muscle Index before Treatment Can Predict a Poorer Prognosis in Advanced Bladder Cancer Patients Who Receive Gemcitabine and Nedaplatin Therapy. Kasahara R, Kawahara T, Ohtake S, Saitoh Y, Tsutsumi S, Teranishi JI, Miyoshi Y, Nakaigawa N, Yao M, Kobayashi K, Uemura H.Biomed Res Int. 2017;2017:7981549. doi: 10.1155/2017/7981549. Epub 2017 Apr 13. PMID: 28497065 Free PMC Article</br>3:Nedaplatin and irinotecan with concurrent thoracic radiotherapy followed by docetaxel consolidation in patients with locally advanced non-small cell lung cancer. Oshita F, Murakami S, Kondo T, Saito H, Yamada K, Nakayama Y.J Exp Ther Oncol. 2017 May;12(1):17-23. PMID: 28472560 </br>4:Phase I study of Nedaplatin, a platinum based antineoplastic drug, combined with nab-paclitaxel in patients with advanced squamous non-small cell lung cancer. Igawa S, Otani S, Nakahara Y, Ryuge S, Hiyoshi Y, Fukui T, Mitsufuji H, Kubota M, Katagiri M, Sato Y, Sasaki J, Masuda N.Invest New Drugs. 2017 May 2. doi: 10.1007/s10637-017-0472-x. [Epub ahead of print] PMID: 28466376 </br>5:Involved-field irradiation concurrently combined with nedaplatin/5-fluorouracil for inoperable esophageal cancer on basis of 18FDG-PET scans: A long follow-up results of phase II study. Yamashita H, Abe O, Nakagawa K.Radiother Oncol. 2017 Apr 17. pii: S0167-8140(17)30141-X. doi: 10.1016/j.radonc.2017.04.002. [Epub ahead of print] No abstract available. PMID: 28427757 </br>6:Clinical efficacy and safety of gemcitabine plus nedaplatin in the treatment of advanced nasopharyngeal carcinoma. Hu Y, Fu JT, Shi D, Feng B, Shi Z.J Cancer Res Ther. 2016 Dec;12(Supplement):C252-C255. doi: 10.4103/0973-1482.200750. PMID: 28230029 Free Article</br>7:[Analysis of Nedaplatin Dose in Patients with Impaired Renal Function]. Araki R, Iwamizu H, Kataoka T, Kumakura Y, Miyazaki M, Nagai T, Ando Y, Yamada K.Gan To Kagaku Ryoho. 2017 Feb;44(2):143-147. Japanese. PMID: 28223671 </br>8:Multi-institutional prospective study of nedaplatin plus S-1 chemotherapy in recurrent and metastatic nasopharyngeal carcinoma patients after failure of platinum-containing regimens. Peng PJ, Lv BJ, Wang ZH, Liao H, Liu YM, Lin Z, Con YY, Huang PY.Ther Adv Med Oncol. 2017 Feb;9(2):68-74. doi: 10.1177/1758834016675099. Epub 2016 Nov 2. PMID: 28203299 Free PMC Article</br>9:Incidence of and risk factors associated with nedaplatin-related hypersensitivity reactions. Kawarada Y, Miyazaki M, Itoh A, Araki R, Iwamizu H, Kataoka T, Kumakura Y, Ota A, Nagai T, Yamada K.Int J Clin Oncol. 2017 Jan 25. doi: 10.1007/s10147-017-1091-4. [Epub ahead of print] PMID: 28124284 </br>10:Nedaplatin enhanced apoptotic effects of ABT-737 in human cancer cells via Mcl-1 inhibition. Zhang C, Li YL, Weng X, Li LY, Zhou MX, Zhang DY, Lin NM.Oncol Lett. 2016 Nov;12(5):4195-4202. Epub 2016 Sep 20. PMID: 27895791 Free PMC Article
|
